Comparative Pharmacology
Head-to-head clinical analysis: FOSAMAX versus RECLAST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOSAMAX versus RECLAST.
FOSAMAX vs RECLAST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone matrix and impairing osteoclast activity through inhibition of farnesyl pyrophosphate synthase.
Inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and inhibiting farnesyl diphosphate synthase (FPPS), a key enzyme in the mevalonate pathway, leading to disruption of osteoclast activity and induction of apoptosis.
70 mg orally once weekly for osteoporosis; 10 mg orally once daily for Paget's disease.
5 mg intravenously over at least 15 minutes once yearly for osteoporosis.
None Documented
None Documented
Terminal elimination half-life is approximately 10.5 years in bone, reflecting slow release from the skeleton. Plasma half-life after intravenous administration is about 1 hour.
The terminal elimination half-life of zoledronic acid in plasma is approximately 146 hours (range 76-250 hours) due to slow release from bone. Clinically, this supports a once-yearly dosing interval for osteoporosis.
Renal excretion of unchanged drug is the primary route (approximately 50% of absorbed dose). Unabsorbed drug is eliminated in feces. No biliary excretion.
Primarily renal; unchanged drug is excreted in urine. Approximately 50% of an absorbed dose is excreted unchanged in urine within 24 hours. The remainder is eliminated via renal excretion over an extended period, with negligible fecal or biliary elimination.
Category C
Category C
Bisphosphonate
Bisphosphonate